Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Medical Technology
  • Guardant wins FDA nod for diagnostic guiding use of AstraZeneca’s Etcamah

Guardant wins FDA nod for diagnostic guiding use of AstraZeneca’s Etcamah

September 7, 2026Posted inMedical Technology

Hot on the heels of the approval for AstraZeneca’s breast cancer drug Etcamah, Guardant Health has been given the green light for its companion diagnostic.

Post navigation

Previous Post
nikkei-225-firms-face-flood-risks-across-industries-and-regions Nikkei 225 firms face flood risks across industries and regions
Next Post
Boston Scientific cyberattack likely to have ‘material impact’ on financial results

Recent Posts

  • Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure
  • 100 Million-Cell AI-Ready Dataset with Single-Cell and Proteomic Data Created by Parse and Nomic
  • Blocking Protein Slows Pancreatic Tumor Growth and Reduces Immune Suppression in Mice
  • No Nonsense: David Liu Lauds Progress in Disease-Agnostic Gene Editing at ESGCT
  • Microbial Sources and Stress Shape the Hidden Endophytes of an Invasive Plant

Archives

  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • September 2024
  • August 2024
  • March 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top